A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy

Trial Profile

A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Bupropion; Ethinylestradiol; Levonorgestrel; Midazolam
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Pharmacodynamics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 31 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 10 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top